Beam Historical Financial Ratios

BEAM Stock

USD 22.19 0.28 1.28%

Beam Therapeutics is presently reporting on over 98 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Dividend Yield of 0.0106, PTB Ratio of 2.92 or Days Sales Outstanding of 1.7 K will help investors to properly organize and evaluate Beam Therapeutics financial condition quickly.

Quick Ratio Current Ratio

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Beam Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

To learn how to invest in Beam Stock, please use our How to Invest in Beam Therapeutics guide.

About Beam Financial Ratios Analysis

Beam TherapeuticsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Beam Therapeutics investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Beam financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Beam Therapeutics history.

Beam Therapeutics Financial Ratios Chart

At this time, Beam Therapeutics' PTB Ratio is very stable compared to the past year. As of the 27th of March 2025, PB Ratio is likely to grow to 2.92, while Book Value Per Share is likely to drop 5.57.

Price To Sales Ratio Dividend Yield Days Sales Outstanding Ev To Sales

Add Fundamental

Price To Sales Ratio

Price to Sales Ratio is figured by comparing Beam Therapeutics stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Beam Therapeutics sales, a figure that is much harder to manipulate than other Beam Therapeutics multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Dividend Yield

Dividend Yield is Beam Therapeutics dividend as a percentage of Beam Therapeutics stock price. Beam Therapeutics dividend yield is a measure of Beam Therapeutics stock productivity, which can be interpreted as interest rate earned on an Beam Therapeutics investment. A financial ratio that shows how much a company pays out in dividends each year relative to its stock price, calculated as annual dividends per share divided by price per share.

Ev To Sales

The Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue.

Most ratios from Beam Therapeutics' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Beam Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Beam Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

To learn how to invest in Beam Stock, please use our How to Invest in Beam Therapeutics guide.At this time, Beam Therapeutics' PTB Ratio is very stable compared to the past year. As of the 27th of March 2025, PB Ratio is likely to grow to 2.92, while Book Value Per Share is likely to drop 5.57.

	2024	2025 (projected)
Dividend Yield	0.0119	0.0106
Price To Sales Ratio	32.14	30.53

Dividend Yield Price To Sales Ratio

Beam Therapeutics fundamentals Correlations

	Price To Sales Ratio	Dividend Yield	Ptb Ratio	Days Sales Outstanding	Book Value Per Share	Free Cash Flow Yield	Operating Cash Flow Per Share	Capex To Depreciation	Pb Ratio	Ev To Sales	Free Cash Flow Per Share	Roic	Inventory Turnover	Net Income Per Share	Days Of Inventory On Hand	Payables Turnover	Capex To Revenue	Cash Per Share	Pocfratio	Interest Coverage	Payout Ratio	Capex To Operating Cash Flow	Pfcf Ratio	Days Payables Outstanding	Income Quality	Roe
Price To Sales Ratio		0.4	-0.18	0.4	-0.52	0.43	0.24	0.31	-0.18	1.0	0.28	0.24	-0.41	0.12	-0.41	-0.52	0.75	-0.54	-0.38	0.28	-0.42	-0.24	-0.16	0.3	-0.2	0.13
Dividend Yield	0.4		-0.32	1.0	-0.22	0.83	0.81	0.46	-0.32	0.4	0.77	0.37	-0.8	0.47	-0.8	-0.72	0.53	-0.17	-0.27	-0.1	-0.94	-0.02	-0.52	0.43	-0.54	0.34
Ptb Ratio	-0.18	-0.32		-0.32	0.8	-0.58	-0.61	-0.95	1.0	-0.18	-0.72	-1.0	0.32	-0.85	0.32	0.45	-0.63	0.73	0.71	-0.25	0.34	0.11	0.75	-0.88	0.37	-0.99
Days Sales Outstanding	0.4	1.0	-0.32		-0.22	0.83	0.81	0.46	-0.32	0.4	0.77	0.37	-0.8	0.47	-0.8	-0.72	0.53	-0.17	-0.27	-0.1	-0.94	-0.02	-0.52	0.42	-0.54	0.34
Book Value Per Share	-0.52	-0.22	0.8	-0.22		-0.43	-0.47	-0.84	0.8	-0.52	-0.6	-0.8	0.3	-0.74	0.3	0.55	-0.89	0.98	0.64	-0.48	0.28	0.22	0.49	-0.84	0.25	-0.74
Free Cash Flow Yield	0.43	0.83	-0.58	0.83	-0.43		0.94	0.69	-0.58	0.43	0.92	0.63	-0.85	0.5	-0.85	-0.86	0.59	-0.31	-0.4	-0.12	-0.89	0.1	-0.84	0.62	-0.81	0.59
Operating Cash Flow Per Share	0.24	0.81	-0.61	0.81	-0.47	0.94		0.72	-0.61	0.24	0.98	0.64	-0.84	0.64	-0.84	-0.84	0.58	-0.37	-0.29	-0.01	-0.87	0.19	-0.84	0.69	-0.78	0.61
Capex To Depreciation	0.31	0.46	-0.95	0.46	-0.84	0.69	0.72		-0.95	0.31	0.82	0.96	-0.46	0.82	-0.46	-0.62	0.77	-0.77	-0.74	0.21	-0.48	-0.21	-0.72	0.98	-0.52	0.92
Pb Ratio	-0.18	-0.32	1.0	-0.32	0.8	-0.58	-0.61	-0.95		-0.18	-0.72	-1.0	0.32	-0.85	0.32	0.45	-0.63	0.73	0.71	-0.25	0.34	0.11	0.75	-0.88	0.37	-0.99
Ev To Sales	1.0	0.4	-0.18	0.4	-0.52	0.43	0.24	0.31	-0.18		0.29	0.24	-0.41	0.12	-0.41	-0.52	0.75	-0.54	-0.38	0.29	-0.43	-0.24	-0.16	0.3	-0.2	0.13
Free Cash Flow Per Share	0.28	0.77	-0.72	0.77	-0.6	0.92	0.98	0.82	-0.72	0.29		0.75	-0.8	0.74	-0.8	-0.83	0.67	-0.51	-0.4	0.09	-0.83	0.13	-0.85	0.79	-0.74	0.72
Roic	0.24	0.37	-1.0	0.37	-0.8	0.63	0.64	0.96	-1.0	0.24	0.75		-0.38	0.85	-0.38	-0.49	0.66	-0.73	-0.73	0.23	-0.4	-0.13	-0.76	0.9	-0.4	0.99
Inventory Turnover	-0.41	-0.8	0.32	-0.8	0.3	-0.85	-0.84	-0.46	0.32	-0.41	-0.8	-0.38		-0.47	1.0	0.72	-0.54	0.22	0.28	0.1	0.96	0.02	0.53	-0.43	0.53	-0.34
Net Income Per Share	0.12	0.47	-0.85	0.47	-0.74	0.5	0.64	0.82	-0.85	0.12	0.74	0.85	-0.47		-0.47	-0.39	0.66	-0.73	-0.54	0.41	-0.5	-0.09	-0.56	0.79	-0.14	0.85
Days Of Inventory On Hand	-0.41	-0.8	0.32	-0.8	0.3	-0.85	-0.84	-0.46	0.32	-0.41	-0.8	-0.38	1.0	-0.47		0.72	-0.54	0.22	0.28	0.1	0.96	0.02	0.53	-0.43	0.53	-0.34
Payables Turnover	-0.52	-0.72	0.45	-0.72	0.55	-0.86	-0.84	-0.62	0.45	-0.52	-0.83	-0.49	0.72	-0.39	0.72		-0.71	0.44	0.35	0.13	0.76	-0.03	0.69	-0.59	0.81	-0.42
Capex To Revenue	0.75	0.53	-0.63	0.53	-0.89	0.59	0.58	0.77	-0.63	0.75	0.67	0.66	-0.54	0.66	-0.54	-0.71		-0.88	-0.64	0.37	-0.56	-0.32	-0.41	0.79	-0.33	0.57
Cash Per Share	-0.54	-0.17	0.73	-0.17	0.98	-0.31	-0.37	-0.77	0.73	-0.54	-0.51	-0.73	0.22	-0.73	0.22	0.44	-0.88		0.58	-0.61	0.21	0.22	0.37	-0.79	0.11	-0.67
Pocfratio	-0.38	-0.27	0.71	-0.27	0.64	-0.4	-0.29	-0.74	0.71	-0.38	-0.4	-0.73	0.28	-0.54	0.28	0.35	-0.64	0.58		0.14	0.29	0.75	0.25	-0.7	0.11	-0.69
Interest Coverage	0.28	-0.1	-0.25	-0.1	-0.48	-0.12	-0.01	0.21	-0.25	0.29	0.09	0.23	0.1	0.41	0.1	0.13	0.37	-0.61	0.14		0.11	0.29	-0.07	0.27	0.23	0.21
Payout Ratio	-0.42	-0.94	0.34	-0.94	0.28	-0.89	-0.87	-0.48	0.34	-0.43	-0.83	-0.4	0.96	-0.5	0.96	0.76	-0.56	0.21	0.29	0.11		0.02	0.56	-0.45	0.56	-0.36
Capex To Operating Cash Flow	-0.24	-0.02	0.11	-0.02	0.22	0.1	0.19	-0.21	0.11	-0.24	0.13	-0.13	0.02	-0.09	0.02	-0.03	-0.32	0.22	0.75	0.29	0.02		-0.42	-0.25	-0.29	-0.08
Pfcf Ratio	-0.16	-0.52	0.75	-0.52	0.49	-0.84	-0.84	-0.72	0.75	-0.16	-0.85	-0.76	0.53	-0.56	0.53	0.69	-0.41	0.37	0.25	-0.07	0.56	-0.42		-0.63	0.78	-0.76
Days Payables Outstanding	0.3	0.43	-0.88	0.42	-0.84	0.62	0.69	0.98	-0.88	0.3	0.79	0.9	-0.43	0.79	-0.43	-0.59	0.79	-0.79	-0.7	0.27	-0.45	-0.25	-0.63		-0.5	0.84
Income Quality	-0.2	-0.54	0.37	-0.54	0.25	-0.81	-0.78	-0.52	0.37	-0.2	-0.74	-0.4	0.53	-0.14	0.53	0.81	-0.33	0.11	0.11	0.23	0.56	-0.29	0.78	-0.5		-0.35
Roe	0.13	0.34	-0.99	0.34	-0.74	0.59	0.61	0.92	-0.99	0.13	0.72	0.99	-0.34	0.85	-0.34	-0.42	0.57	-0.67	-0.69	0.21	-0.36	-0.08	-0.76	0.84	-0.35

Click cells to compare fundamentals

Beam Therapeutics Account Relationship Matchups

High Positive Relationship

Ev To Sales	+ 1.0	Price To Sales Ratio
Days Sales Outstanding	+ 1.0	Dividend Yield
Pb Ratio	+ 1.0	Ptb Ratio
Days Of Inventory On Hand	+ 1.0	Inventory Turnover
Roe	+ 0.99	Roic
Cash Per Share	+ 0.98	Book Value Per Share

High Negative Relationship

Roic	- 1.0	Pb Ratio
Roic	- 1.0	Ptb Ratio
Roe	- 0.99	Pb Ratio
Roe	- 0.99	Ptb Ratio
Pb Ratio	- 0.95	Capex To Depreciation
Capex To Depreciation	- 0.95	Ptb Ratio

Beam Therapeutics fundamentals Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Price To Sales Ratio	159.0K	98.73	44.95	5.56	32.14	30.53
Ptb Ratio	15.54	6.19	3.73	2.14	2.78	2.92
Book Value Per Share	5.25	12.87	10.48	12.72	8.91	5.57
Free Cash Flow Yield	(0.0878)	(0.0294)	(0.0221)	(0.00965)	(0.0871)	(0.17)
Operating Cash Flow Per Share	(2.05)	(1.03)	0.32	(1.93)	(4.22)	(4.01)
Stock Based Compensation To Revenue	640.83	0.84	1.38	0.26	0.3	0.29
Capex To Depreciation	3.45	6.28	3.46	1.69	0.28	0.27
Pb Ratio	15.54	6.19	3.73	2.14	2.78	2.92
Ev To Sales	156.4K	82.84	44.07	4.86	30.24	28.73
Free Cash Flow Per Share	(2.4)	(1.76)	(0.38)	(2.37)	(4.33)	(4.11)
Roic	(0.49)	(0.28)	(0.3)	(0.14)	(0.44)	(0.42)
Net Income Per Share	(5.49)	(5.31)	(3.76)	(1.72)	(4.58)	(4.81)
Payables Turnover	16.34	2.2	2.5	270.49	243.44	255.61
Sales General And Administrative To Revenue	1.2K	1.1	1.44	0.31	1.76	1.67
Research And Ddevelopement To Revenue	4.3K	7.47	5.11	1.16	5.79	5.5
Capex To Revenue	681.54	0.9	0.8	0.0893	0.14	0.13
Cash Per Share	6.41	21.35	15.4	15.42	10.34	7.5
Pocfratio	(39.85)	(77.24)	121.56	(14.08)	(5.88)	(6.17)
Pfcf Ratio	(34.04)	(45.26)	(103.63)	(11.48)	(5.73)	(6.02)
Days Payables Outstanding	22.34	165.93	145.97	1.35	1.55	1.47
Income Quality	0.92	0.49	0.18	(0.0779)	1.13	0.97
Roe	(1.04)	(0.41)	(0.36)	(0.14)	(0.51)	(0.54)
Ev To Operating Cash Flow	(39.2)	(64.81)	119.17	(12.31)	(5.53)	(5.81)
Pe Ratio	(14.88)	(14.99)	(10.39)	(15.85)	(5.42)	(5.69)
Return On Tangible Assets	(0.57)	(0.23)	(0.2)	(0.0908)	(0.34)	(0.36)
Ev To Free Cash Flow	(33.48)	(37.98)	(101.59)	(10.04)	(5.39)	(5.66)
Earnings Yield	(0.0672)	(0.0667)	(0.0963)	(0.0631)	(0.18)	(0.19)
Net Debt To E B I T D A	0.48	2.1	0.17	1.68	0.29	0.28
Current Ratio	3.01	4.52	4.89	5.89	4.82	3.25
Tangible Book Value Per Share	5.25	12.87	10.48	12.72	8.91	5.57
Shareholders Equity Per Share	5.25	12.87	10.48	12.72	8.91	5.57
Debt To Equity	0.41	0.17	0.24	0.18	0.22	0.14
Capex Per Share	0.35	0.73	0.7	0.44	0.11	0.1
Graham Net Net	2.0	10.04	6.71	9.22	5.84	3.74
Revenue Per Share	5.14E-4	0.81	0.87	4.9	0.77	0.98
Interest Debt Per Share	2.18	2.22	2.78	2.24	1.96	1.37
Debt To Assets	0.22	0.0965	0.13	0.12	0.15	0.21
Enterprise Value Over E B I T D A	(29.32)	(10.94)	(8.28)	(11.74)	(4.62)	(4.85)

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Beam Therapeutics is a strong investment it is important to analyze Beam Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Beam Therapeutics' future performance. For an informed investment choice regarding Beam Stock, refer to the following important reports:

How To Invest In Beam

Details

Is Beam Stock a good investment?

Details

What is Beam Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

To learn how to invest in Beam Stock, please use our How to Invest in Beam Therapeutics guide.

You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Beam Therapeutics. If investors know Beam will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Beam Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(4.58)

Revenue Per Share

0.772

Quarterly Revenue Growth

(0.91)

Return On Assets

(0.20)

Return On Equity

(0.44)

The market value of Beam Therapeutics is measured differently than its book value, which is the value of Beam that is recorded on the company's balance sheet. Investors also form their own opinion of Beam Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Beam Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Beam Therapeutics' market value can be influenced by many factors that don't directly affect Beam Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Beam Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Beam Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Beam Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Beam Historical Financial Ratios

About Beam Financial Ratios Analysis

Beam Therapeutics Financial Ratios Chart

Price To Sales Ratio

Dividend Yield

Ev To Sales

Beam Therapeutics fundamentals Correlations

Beam Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Beam Therapeutics fundamentals Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY